[1] Kearon C, Akl EA, Ornelas J, et al. Antithrombotic Therapy for VTE Disease: CHEST Guideline and Expert Panel Report[J]. Chest, 2016,149(2):315-352. DOI: 10.1016/j.chest.2015.11.026.

[2] Torbicki A, Perrier A, Konstantinides S, et al. Guidelines on the diagnosis and management of acute pulmonary embolism: the Task Force for the Diagnosis and Management of Acute Pulmonary Embolism of the European Society of Cardiology (ESC)[J]. Eur Heart J, 2008,29(18):2276-2315. DOI: 10.1093/eurheartj/ehn310.

[3] Warkentin TE. New approaches to the diagnosis of heparin-induced thrombocytopenia[J]. Chest, 2005,127(2 Suppl):35S-45S. DOI: 10.1378/chest.127.2_suppl.35S.

[4] Cuker A, Gimotty PA, Crowther MA, et al. Predictive value of the 4Ts scoring system for heparin-induced thrombocytopenia: a systematic review and meta-analysis[J]. Blood, 2012,120(20):4160-4167. DOI: 10.1182/blood-2012-07-443051.

[5] Nagler M, Bachmann LM, ten CH, et al. Diagnostic value of immunoassays for heparin-induced thrombocytopenia: a systematic review and meta-analysis[J]. Blood, 2016,127(5):546-557. DOI: 10.1182/blood-2015-07-661215.

[6] Sun L, Gimotty PA, Lakshmanan S, et al. Diagnostic accuracy of rapid immunoassays for heparin-induced thrombocytopenia. A systematic review and meta-analysis[J]. Thromb Haemost, 2016,115(5):1044-1055. DOI: 10.1160/TH15-06-0523.

[7] Douketis J, Tosetto A, Marcucci M, et al.Risk of recurrence after venous thromboembolism in men and women: patient level meta-analysis[J]. BMJ, 2011,342:d813.